From shift workers to flight attendants, disruptions in circadian rhythms are a risk factor for metabolic disorders. Several sessions held at the recent EASL meeting focused on that link, and how disturbances in the internal clock may increase the risk of hepatic disorders. Read More
Glioblastoma is a particularly aggressive form of brain cancer characterized by rapid infiltration into surrounding brain tissue, especially in areas of increased neuronal activity. Neurons and nerve fibers have recently been identified as vital components of the tumor microenvironment that favor the initiation and progression of a variety of solid tumors, including gliomas. Researchers have gained new insights into the molecular mechanisms driving glioblastoma infiltration and identified subtypes of neurons that serve as the substrate for driving tumor progression. Read More
Domain Therapeutics SA has nominated a novel drug candidate, DT-7012, an anti-CCR8 monoclonal antibody depleting tumor-infiltrating regulatory T cells (Tregs). Read More
Researchers from Parthenon Therapeutics Inc. and affiliated organizations presented preclinical data for a novel antiepithelial discoidin domain-containing receptor 1 (DDR1) antibody, PRTH-101, being developed for the treatment of cancer. Read More
Suzhou Genhouse Bio Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer and more. Read More
Researchers from Enterin Inc. and affiliated organizations presented preclinical data for ENT-03, an endogenous spermine bile acid with PTP1B inhibitory activity, being developed as a therapy to normalize glycemia and reverse obesity. Read More
Recent genome-wide association studies have elucidated a spliced variant (rs72613567:TA) in 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) found to be associated with decreased risk of chronic liver disorders. The presence of this variant also correlates with delayed onset of autoimmune hepatitis in carriers. Read More
Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis. Read More
Sangamo Therapeutics Inc. and Voyager Therapeutics Inc. have entered into a definitive license agreement for a potential treatment for prion disease. Read More
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified EGFR (HER1; erbB1) wild-type and/or mutant inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer (NSCLC). Read More
Etnova Therapeutics Co. Ltd. has described gadolinium complexes reported to be useful for the treatment of stroke, ataxia, epilepsy, spinal cord injury, optic nerve injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others. Read More
